News

The company expects to recruit around 500 patients at 15 sites in China. Boston Scienific received CE Mark approval for the Promus Element Everolimus-Eluting Stent System in October

CCX832 is the fourth and final drug candidate discovered and developed by ChemoCentryx under its alliance with GlaxoSmithKline (GSK) to identify molecules targeting four specific chemokine and chemoattractant

As per the terms of the agreement, Teva Pharma has licensed APP Pharma to market Gemcitabine HCI for Injection in 200mg and 1g single dose vials during the

Mylan said that the generic name of Caduet tablets is Amlodipine Besylate/Atorvastatin Calcium tablets. Pursuant to the settlement agreement, pending litigation will be dismissed and Mylan may begin

Dupont said the new coverall performs three functions – protects the wearer, protects the products and processes, and offers comfort to the wearer. The Tyvek Labo coverall protects

The new license means that Android is now available for the symptomatic treatment of rheumatoid arthritis, osteoarthritis or ankylosing spondylitis. Axorid, which is to be taken as a

Perampanel is a selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy. Accoding to

Nuvigil is indicated to improve wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea (OSA), shift work disorder (SWD), or narcolepsy. The trial evaluated patients

Gilead Sciences generated a net income of $629.42m for the fourth quarter 2010, or $0.76 per diluted share, compared to $802.21m, or $0.87 per diluted share, against the